fda warning letters compounded semaglutide september 2025 Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling September 15, 2025: Telehealth company

Rivals are flooding in, with dozens of compounds already in mid- to late-stage trials

The main renal dysfunctions are due to the thickening of the glomerular basement membranes, formed of microaneurysms and development of mesangial nodules

What SURMOUNT-5 revealed is a meaningful difference in how often those side effects cause patients to stop treatment: GI-related discontinuation was 2.7% with tirzepatide vs

However, according to the UKs Medicines and Healthcare products Regulatory Agency (MHRA), the most common side effects of GLP-1 medications are digestive issues, including constipation, diarrhoea, loss of appetite, nausea and vomiting

Updated January 30, 2025

J Neurochem 146(2):173185